Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Gloriana, Ndembe"'
Autor:
Gloriana Ndembe, Ilenia Intini, Massimo Moro, Chiara Grasselli, Andrea Panfili, Nicolò Panini, Augusto Bleve, Mario Occhipinti, Cristina Borzi, Marina Chiara Garassino, Mirko Marabese, Simone Canesi, Eugenio Scanziani, Gabriella Sozzi, Massimo Broggini, Monica Ganzinelli
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-18 (2024)
Abstract Background About 10% of NSCLCs are mutated in KRAS and impaired in STK11/LKB1, a genetic background associated with poor prognosis, caused by an increase in metastatic burden and resistance to standard therapy. LKB1 is a protein involved in
Externí odkaz:
https://doaj.org/article/9430de048d034f9d86dd3b0f84f29a05
Autor:
Paolo Mendogni, Roberta Affatato, Enrico Cabri, Michela Chiappa, Gloriana Ndembe, Davide Tosi, Alessandro Del Gobbo, Maddalena Fratelli, Eleonora Pardini, Iacopo Petrini, Lorenzo Rosso, Massimo Broggini, Mirko Marabese
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-6 (2022)
Abstract Background Thymic malignancies are a heterogeneous group of rare cancers for which systemic chemotherapy is the standard treatment in the setting of advanced, recurrent or refractory diseases. Both environmental and genetic risk factors have
Externí odkaz:
https://doaj.org/article/37f8229025cc48cb86b2eeb6c78c48d2
Autor:
Gloriana Ndembe, Ilenia Intini, Elisa Perin, Mirko Marabese, Elisa Caiola, Paolo Mendogni, Lorenzo Rosso, Massimo Broggini, Marika Colombo
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
LKB1 (liver kinase B1) is a master regulator of several processes such as metabolism, proliferation, cell polarity and immunity. About one third of non-small cell lung cancers (NSCLCs) present LKB1 alterations, which almost invariably lead to protein
Externí odkaz:
https://doaj.org/article/8433b15eaf0046ca8d4f118ed1971f7a
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 16(8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8821decf357cfbd708fbbc454f9366a6
https://pubmed.ncbi.nlm.nih.gov/33971321
https://pubmed.ncbi.nlm.nih.gov/33971321
Autor:
Marina Chiara Garassino, Amanda Psyrri, Michele Milella, Helena Linardou, Fabiana Letizia Cecere, Maria Francesca Alvisi, Eliana Rulli, Anna Cecilia Bettini, Gloriana Ndembe, Marcella De Maglie, Samuel S. Murray, Pierpaolo Romanelli, Massimo Broggini, Giuseppe Lo Russo, Mirko Marabese, Monica Ganzinelli, Alessandra Fabbri, Elisa Caiola
Publikováno v:
Journal of Clinical Medicine
Volume 9
Issue 8
Journal of Clinical Medicine, Vol 9, Iss 2438, p 2438 (2020)
Volume 9
Issue 8
Journal of Clinical Medicine, Vol 9, Iss 2438, p 2438 (2020)
Clinical data suggest that only a subgroup of non-small cell lung cancer (NSCLC) patients has long-term benefits after front-line platinum-based therapy. We prospectively investigate whether KRAS status and DNA polymerase &beta
expression could
expression could
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::541ded3bb5ce98db8765a5f8217aeb68
Autor:
Maria Francesca, Alvisi, Monica, Ganzinelli, Helena, Linardou, Elisa, Caiola, Giuseppe, Lo Russo, Fabiana Letizia, Cecere, Anna Cecilia, Bettini, Amanda, Psyrri, Michele, Milella, Eliana, Rulli, Alessandra, Fabbri, Marcella, De Maglie, Pierpaolo, Romanelli, Samuel, Murray, Gloriana, Ndembe, Massimo, Broggini, Marina Chiara, Garassino, Mirko, Marabese
Publikováno v:
Journal of Clinical Medicine
Clinical data suggest that only a subgroup of non-small cell lung cancer (NSCLC) patients has long-term benefits after front-line platinum-based therapy. We prospectively investigate whether KRAS status and DNA polymerase β expression could help ide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c8e74d5f0a4c0b02a9135f8d7186b7ef
https://pubmed.ncbi.nlm.nih.gov/32751518
https://pubmed.ncbi.nlm.nih.gov/32751518